1-2 of 2
Marjo Hahka-Kemppinen, MD PhD
Close
Sort by
Journal Articles

Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Franck Morschhauser, MD PhD, Kamal Bouabdallah, MD, Stephan Stilgenbauer, MD, Catherine Thieblemont, MD PhD, Martin Wolf, MD, Sophie de Guibert, MD, Florian Zettl, MD, Marjo Hahka-Kemppinen, MD PhD, David Xiaohui Wang, MD PhD, Patrick Brueck, MD, Charles Caldwell, MD, Richard Beckmann, PhD, Lawrence Gelbert, PhD, Damien Cronier, PhD, Ji Lin, PhD, Lily Li, MD, Edward M. Chan, MD, Michael Pfreundschuh, Martin Wilhem, MD, Georg Hess, MD
Journal: Blood
Blood (2014) 124 (21): 3067.
https://doi.org/10.1182/blood.V124.21.3067.3067
Published: 2014
Journal Articles

A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial

Michael Crump, MD FRCPC, Sirpa Leppä, Luis E Fayad, Je-Jung Lee, Alice Di Rocco, MD, Michinori Ogura, MD, PhD, Hans Hagberg, Frederick Schnell, Robert M Rifkin, MD, Andreas Mackensen, Fritz Offner, MD, Lauren Pinter-Brown, MD, Sonali M. Smith, MD, Kensei Tobinai, MD, PhD, Su-Peng Yeh, MD, Jun Zhu, Marjo Hahka-Kemppinen, MD, PhD, Donald Thornton, MD, Peipei Shi, Ph.D., Boris Lin, MD, PhD, Brad S. Kahl, MD, Norbert Schmitz, Kerry J. Savage, MD, MSc, Thomas M Habermann, MD
Journal: Blood
Blood (2013) 122 (21): 371.
https://doi.org/10.1182/blood.V122.21.371.371
Published: 2013